Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | AKT2 | P31751 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25361841 | 0.82 | KIF11 (0.53) | KIF11KDM4ENPC1 | |
| SCHEMBL3805973 | 0.81 | KIF11 (0.41) | AKT1AKT2KIF11 | |
| SCHEMBL4167951 | 0.80 | KIF11 (0.37) | KIF11 | |
| SCHEMBL10845996 | 0.77 | AKT1 (0.31) | AKT1AKT2 | |
| SCHEMBL7954401 | 0.76 | MAP4K4 (0.40) | KDM4ENPC1RAB9A | |
| SCHEMBL17164814 | 0.74 | PDE2A (0.54) | AKT1AKT2KIF11PDE2ASCN10A | |
| SCHEMBL6291238 | 0.74 | — | — | |
| SCHEMBL3668376 | 0.73 | KIF11 (0.32) | KIF11 | |
| SCHEMBL3673418 | 0.72 | ADRB2 (0.38) | PDE2A | |
| SCHEMBL4173599 | 0.72 | CHEK1 (0.33) | KIF11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021117846-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | 日本新薬株式会社 | 2021-06-17 | — | — | WO | claimed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | claimed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | claimed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | claimed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
| WO-2021117846-A1 | COMPOUND SERVING AS PDGF RECEPTOR KINASE INHIBITOR, AND COMPOSITION | 日本新薬株式会社 | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | AKT1 2393/4885AKT2 2270/4885KIF11 4342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.